Abstract
Background: The use of preparations from Bryophyllum pinnatum for tocolysis (or to arrest labor) is supported by observations obtained mainly at empirical level, but also by preclinical experiments performed with uterus strips and myometrium cell lines. Furthermore, a retrospective matched-pair study revealed good tolerability and effectiveness. In anthroposophic medicine, however, Bryophyllum species are used for a broad spectrum of diagnoses. Here, we characterize the prescribing pattern of Bryophyllum preparations in a network of anthroposophic physicians in Germany. Methods: 38 primary-care physicians in Germany participated in the EvaMed network, a multi-center observational study. They documented anonymized prescriptions, diagnoses and demographic data (age and gender) for each consecutive patient between 01.01.2004 and 01.01.2010. Diagnoses were coded according to the 10th revision of the International Classification of Diseases (ICD-10). In the present analysis, all prescriptions of any Bryophyllum preparation in the resulting data bank were identified and the corresponding diagnoses were analyzed retrospectively. Results: A total of 4,038 prescriptions of Bryophyllum preparations were identified in the EvaMed data bank. A variety of preparations could be found, 77.7% of which were prepared from Bryophyllum plants exclusively and 22.5% were combinations. Bryophyllum preparations were often prescribed to treat ‘mental and behavioral disorders’ (ICD-10 F00–F99, 35.7%) and ‘diseases of the skin and subcutaneous tissue’ (L00–L99, 16.0%), followed by ‘symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified diseases’ (R00–R99, 15.2%) and ‘diseases of the nervous system’ (G00– G99, 9.7%). Conclusion: By revealing the use of Bryophyllum preparations in so many other indications than preterm delivery, our data clearly show the urgent need to conduct additional clinical trials.
Journal Section:
Original Article <i>· </i> Originalarbeit
References
1.
Kamboj A, Saluja A: Bryophyllum pinnatum (Lam.) Kurz.: Phytochemical and pharmacological profile: a review. Phcog Rev 2009;3:364–374.
2.
Yadav NP, Dixit VK: Hepatoprotective activity of leaves of Kalanchoe pinnata Pers. J Ethnopharmacol 2003;86:197–202.
[PubMed]
3.
El Abdellaoui S, Destandau E, Toriboi A, et al.: Bioactive molecules in Kalanchoe pinnata leaves: extraction, purification, and identification. Anal Bioanal Chem 2010;398:1329–1338.
[PubMed]
4.
Lans CA: Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. J Ethnobiol Ethnomed 2006;2:45.
[PubMed]
5.
Nayak BS, Marshall JR, Isitor G: Wound healing potential of ethanolic extract of Kalanchoe pinnata Lam. leaf – a preliminary study. Indian J Exp Biol 2010;48:572–576.
[PubMed]
6.
Kamgang R, Mboumi RY, Fondjo AF, Tagne MA, N’dillé GP, Yonkeu JN: Antihyperglycaemic potential of the water-ethanol extract of Kalanchoe crenata (Crassulaceae). J Nat Med 2008;62:34–40.
[PubMed]
7.
Ojewole JA: Antinociceptive, anti-inflammatory and antidiabetic effects of Bryophyllum pinnatum (Crassulaceae) leaf aqueous extract. J Ethnopharmacol 2005;99:13–19.
[PubMed]
8.
Hamre HJ, Witt CM, Glockmann A, Tröger W, Willich SN, Kiene H: Use and safety of anthroposophic medications in chronic disease: a 2-year prospective analysis. Drug Saf 2006;29:1173–1189.
[PubMed]
9.
Kienle G, Kiene H, Albonico H-U: Anthroposophic Medicine – Effectiveness, Utility, Costs, Safety. Stuttgart, Schattauer, 2006.
10.
Hassauer W, Schreiber K, Von der Decken D: Ein neuer Weg in der tokolytischen Therapie. Erfahrungsheilkunde 1985;34:683–687.
11.
Daub E: Vorzeitige Wehentätigkeit. Ihre Behandlung mit pflanzlichen Substanzen, eine klinische Studie. Stuttgart, Urachhaus, 1989.
12.
Vilaghy I: Decreasing the rate of premature delivery with phytotherapy – results from general practice. (In German). Ther Umsch 2002;59:696–701.
[PubMed]
13.
Plangger N, Rist R, Zimmermann R, von Mandach U: Intravenous tocolysis with Bryophyllum pinnatum is better tolerated than beta-agonist application. Eur J Obstet Gynecol Reprod Biol 2006;124: 168–172.
[PubMed]
14.
Gwehenberger B, Rist L, Huch R, von Mandach U: Effect of Bryophyllum pinnatum versus fenoterol on uterine contractility. Eur J Obstet Gynecol Reprod Biol 2004;113:164–171.
[PubMed]
15.
Wächter R, Brenneisen R, Hamburger M, Mennet M, Schnelle M, Worel AM, Simões-Wüst AP, von Mandach U: Leaf press juice from Bryophyllum pinnatum (Lamarck) Oken induces myometrial relaxation. Phytomedicine 2011;19:74–82.
[PubMed]
16.
Simões-Wüst AP, Grãos M, Duarte CB, Brenneisen R, Hamburger M, Mennet M, Ramos MH, Schnelle M, Wächter R, Worel AM, von Mandach U: Juice of Bryophyllum pinnatum (Lam.) inhibits oxytocin-induced increase of the intracellular calcium concentration in human myometrial cells. Phytomedicine 2010;17:980–986.
[PubMed]
17.
Commission C: Monographien Kommission C. Bundesanzeiger 1992;121:272–277.
18.
Gesellschaft Anthroposophischer Ärzte in Deutschland e.V. und Medizinische Sektion der Freien Hochschule für Geisteswissenschaft Dornach/ Schweiz: Vademecum Anthroposophische Arzneimittel. Der Merkurstab 2008;61.
19.
Jeschke E, Ostermann T, Tabali M, et al.: Diagnostic profiles and prescribing patterns in everyday anthroposophic medical practice – a prospective multi-centre study. Forsch Komplementmed 2009; 16:325–333.
[PubMed]
20.
Jeschke E, Ostermann T, Vollmar HC, et al.: Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians. BMC Neurol 2011;11:99.
[PubMed]
21.
Jeschke E, Ostermann T, Lüke C, Tabali M, Kröz M, Bockelbrink A, Witt CM, Willich SN, Matthes H: Remedies containing Asteraceae extracts: a prospective observational study of prescribing patterns and adverse drug reactions in German primary care. Drug Saf 2009;32:691–706.
[PubMed]
22.
Jeschke E, Ostermann T, Tabali M, Kröz M, Bockelbrink A, Witt CM, Willich SN, Matthes H: Anthroposophic medicine in pediatric primary care: a prospective, multicenter observational study on prescribing patterns. Altern Ther Health Med 2011; 17:18–28.
[PubMed]
23.
Jeschke E, Ostermann T, Tabali M, Vollmar HC, Kröz M, Bockelbrink A, Witt CM, Willich SN, Matthes H: Pharmacotherapy of elderly patients in everyday anthroposophic medical practice: a prospective, multicenter observational study. BMC Geriatr 2010;10:48.
[PubMed]
24.
Jeschke E, Ostermann T, Vollmar HC, Kröz M, Bockelbrink A, Witt CM, Willich SN, Matthes H: Evaluation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: a prospective observational study. BMC Fam Pract 2009;10:78.
[PubMed]
25.
Arbeitsgruppe Erhebung und Nutzung von Sekundärdaten der Deutschen Gesellschaft für Sozialmedizin und Prävention, Arbeitsgruppe Epidemiologische Methoden der Deutschen Gesellschaft für Epidemiologie, Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie, Deutschen Gesellschaft für Sozialmedizin und Prävention: Good practice of secondary data analysis, first revision. (In German). Gesundheitswesen 2008; 70:54-60.
[PubMed]
26.
Chenot J-F, Heidenreich R: The role of ethics committes in primary care research projects. Z Allg Med 2004;80:271-291.
27.
Mercier A, Auger-Aubin I, Lebeau J-P, Van Royen P, Peremans L: Understanding the prescription of antidepressants: a qualitative study among French GPs. BMC Fam Pract 2011;12:99.
[PubMed]
28.
Kjosavik SR, Hunskaar S, Aarsland D, Ruths S: Initial prescription of antipsychotics and anti-depressants in general practice and specialist care in Norway. Acta Psychiatr Scand 2011;123:459-465.
[PubMed]
29.
Gaind KN, Gupta RL: Flavonoid glycosides from Kalanchoe pinnata. Planta Med 1971;20:368-373.
[PubMed]
30.
Muzitano MF, Bergonzi MC, De Melo GO, Lage CL, Bilia AR, Vincieri FF, Rossi-Bergmann B, Costa SS: Influence of cultivation conditions, season of collection and extraction method on the content of antileishmanial flavonoids from Kalanchoe pinnata. J Ethnopharmacol 2011;133:132-137.
[PubMed]
31.
Muzitano MF, Tinoco LW, Guette C, Kaiser CR, Rossi-Bergmann B, Costa SS: The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry 2006;67:2071-2077.
[PubMed]
32.
Cao H, Xia J, Xu D, Lu B, Chen G: The separation and identification of the flavonoids from the leaves of Bryophyllum pinnatum. (In Chinese). Zhong Yao Cai 2005;28:988-990.
[PubMed]
33.
Supratman U, Fujita T, Akiyama K, Hayashi H: New insecticidal bufadienolide, bryophyllin C, from Kalanchoe pinnata. Biosci Biotechnol Bio-chem 2000;64:1310-1312.
[PubMed]
34.
Supratman U, Fujita T, Akiyama K, Hayashi H, Murakami A, Sakai H, Koshimizu K, Ohigashi H: Anti-tumor promoting activity of bufadienolides from Kalanchoe pinnata and K. daigremontiana × tubiflora. Biosci Biotechnol Biochem 2001;65:947-949.
[PubMed]
35.
Gaind KN, Gupta RL: Phenolic components from the leaves of Kalanchoe pinnata. Planta Med 1973;23:149-153.
[PubMed]
36.
Nassis CZ, Haebisch EM, Giesbrecht AM: Antihistamine activity of Bryophyllum calycinum. Braz J Med Biol Res 1992;25:929–936.
[PubMed]
37.
Cruz EA, Da-Silva SA, Muzitano MF, Silva PM, Costa SS, Rossi-Bergmann B: Immunomodulatory pretreatment with Kalanchoe pinnata extract and its quercitrin flavonoid effectively protects mice against fatal anaphylactic shock. Int Immunopharmacol 2008;8:1616–1621.
[PubMed]
38.
Cruz EA, Reuter S, Martin H, Dehzad N, Muzitano MF, Costa SS, Rossi-Bergmann B, Buhl R, Stassen M, Taube C: Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease. Phytomedicine 2012;19:115–121.
[PubMed]
39.
Pal S, Sen T, Chaudhuri AK: Neuropsychopharmacological profile of the methanolic fraction of Bryophyllum pinnatum leaf extract. J Pharm Pharmacol 1999;51:313–318.
[PubMed]
40.
Yemitan OK, Salahdeen HM: Neurosedative and muscle relaxant activities of aqueous extract of Bryophyllum pinnatum. Fitoterapia 2005;76:187– 193.
[PubMed]
41.
Ojewole J: Antihypertensive properties of Bryophyllum pinnatum (Lamarck) Oken leaf extracts. Am J Hypertens 2002;15:34A–39
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
